Patents by Inventor Ann Marie Leen

Ann Marie Leen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250032617
    Abstract: Embodiments of the disclosure include methods and compositions for producing T cell receptor (TCR) polypeptides specific for hematological neoantigens. In specific embodiments. T cells directed to one or more hematological neoantigens are produced following exposure of PBMCs to peptides that encompass one or more neoantigens, and the TCRs in the produced T cells are tested for efficacy and identified. The neoantigen-specific TCRs are utilized in a variety of immunotherapies.
    Type: Application
    Filed: October 7, 2022
    Publication date: January 30, 2025
    Applicant: Baylor College of Medicine
    Inventors: Wingchi Leung, Premal Lulla, Ann Marie Leen, Valentina Hoyos, Paul Shafer
  • Publication number: 20250009870
    Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.
    Type: Application
    Filed: February 7, 2024
    Publication date: January 9, 2025
    Applicant: Baylor College of Medicine
    Inventors: Ann Marie Leen, Pailbel Aguayo-Hiraldo, Ifigeneia Tzannou, Juan F. Vera Valdes
  • Publication number: 20240335537
    Abstract: Disclosed herein are methods and compositions for modulating immune responses by using decoy molecules to bind to soluble or other ligands. In specific embodiments, the decoy molecules comprise a domain that binds to a target immunosuppressive ligand and another domain that releases immunostimulatory signals when activated. In specific embodiments, the decoy molecules are soluble and are secreted by transgenic T cells at a tumor site, such as upon antigen engagement, and they protect the transgenic cells themselves and also bystander (e.g., non-modified) endogenous immune cells.
    Type: Application
    Filed: August 12, 2022
    Publication date: October 10, 2024
    Applicant: Baylor College of Medicine
    Inventors: Pradip Bajgain, Juan Fernando Vera Valdes, Ann Marie Leen, Mohsen Basiri
  • Publication number: 20240325447
    Abstract: Embodiments of the disclosure include methods and compositions in which adoptive T cell therapy is generated by particular methods in which a population of the T cells are directed against one or more neoantigens of any kind. In specific embodiments, the T cells are produced following exposure of PBMCs to peptides that encompass one or more antigens, and the produced T cells are tested for their efficacy. Following identification of efficacious peptides, they are utilized to produce the adoptive T cell therapy against the neoantigen(s).
    Type: Application
    Filed: October 6, 2022
    Publication date: October 3, 2024
    Applicant: Baylor College of Medicine
    Inventors: Ann Marie Leen, Wingchi Leung, Premal Lulla
  • Patent number: 11981923
    Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: May 14, 2024
    Assignee: Baylor College of Medicine
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
  • Patent number: 11931408
    Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: March 19, 2024
    Assignee: Baylor College of Medicine
    Inventors: Ann Marie Leen, Pailbel Aguayo-Hiraldo, Ifigeneia Tzannou, Juan F. Vera Valdes
  • Publication number: 20230357721
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 9, 2023
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Publication number: 20230295565
    Abstract: Embodiments of the disclosure include universal antigen-specific T cell compositions, and methods of making and using the same. Embodiments of the disclosure also include methods of identifying and selecting suitable donors for use in constructing donor minibanks of antigen-specific T cell lines; donor minibanks of antigen-specific T cell lines; universal antigen-specific T cell compositions comprising a plurality of the antigen specific T cell lines from such donor minibanks, and donor banks made up of a plurality of such minibanks. The present disclosure includes methods of treating a disease or condition comprising administering to a patient at least one universal antigen-specific T cell composition disclosed herein.
    Type: Application
    Filed: February 2, 2021
    Publication date: September 21, 2023
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes
  • Publication number: 20230293580
    Abstract: Embodiments of the disclosure concern polyclonal SARS-CoV2 virus specific T cell lines and methods of using the same to treat and prevent viral infections.
    Type: Application
    Filed: March 19, 2021
    Publication date: September 21, 2023
    Inventors: Ann Marie Leen, Spyridoula Vasileiou
  • Patent number: 11717538
    Abstract: The present invention concerns compositions and methods related to approaches to render ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. In particular embodiments, tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulaotyr/activating signal. In specific embodiments, the T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: August 8, 2023
    Assignee: Baylor College of Medicine
    Inventors: Ann Marie Leen, Juan F. Vera
  • Publication number: 20230210901
    Abstract: Embodiments of the disclosure include methods and compositions for inhibiting the immune suppressive tumor microenvironment using cell therapy wherein the cells express a chimeric protein having an extracellular domain that binds TRAIL-R2 and an intracellular domain that in specific embodiments comprises one or more costimulatory domains that enhance activity of the cells upon activation. In specific embodiments, the chimeric protein comprises an scFv that targets TRAIL-R2 and an intracellular region that comprises a costimulatory domain from 4-1BB. In particular embodiments, the cells also express a therapeutic protein, such as a chimeric antigen receptor.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 6, 2023
    Inventors: Valentina Hoyos, Saisha Nalawade, Ann Marie Leen, Helen E. Heslop, Juan Fernando Vera Valdes, Malcolm Brenner, Cliona M. Rooney
  • Publication number: 20230114971
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 13, 2023
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Publication number: 20230028788
    Abstract: The present disclosure provides, inter alia, compositions and methods for harnessing the immune system (e.g., T cells) as a detection tool to diagnose and predict cancer patient treatment outcomes and for monitoring the persistence of functional, non-genetically modified, T cell therapies in vivo after administration to a subject.
    Type: Application
    Filed: December 18, 2020
    Publication date: January 26, 2023
    Inventors: Wingchi Leung, Premal Lulla, Spyridoula Vasileiou, Ann Marie Leen, Juan F. Vera Valdes
  • Publication number: 20220288119
    Abstract: The present disclosure includes compositions and methods for preventing viral infection and/or preventing reactivation of a latent virus in a subject. The methods involve prophylactically administering at least one antigen-specific T cell line from a third party donor and/or a donor minibank and/or a donor bank to a subject. The subject may be a patient who has received a transplant (e.g., a tissue, solid organ, or bone marrow transplant) or who is in need of such a transplant, or is immunosuppressed or in need of immunosuppressive therapy.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 15, 2022
    Inventors: Juan Fernando Vera, Valdes, Ann Marie Leen, Ifigeneia Tzannou
  • Publication number: 20220282218
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 8, 2022
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Publication number: 20220257654
    Abstract: Embodiments of the disclosure include methods of identifying and selecting suitable donors for use in constructing donor minibanks of antigen-specific T cell lines; donor minibanks of antigen-specific T cell lines; and donor banks made up of a plurality of such minibanks. The present disclosure includes methods of treating a disease or condition comprising administering at least one antigen-specific T cell line from such a donor minibank or donor bank to patient (e.g., who has received transplanted material from a transplant donor in a transplant procedure), and methods for selecting the best HLA-matched antigen-specific T cell line in the donor minibank for a particular patient.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 18, 2022
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Juan Fernando VERA VALDES, Ann Marie LEEN, Ifigeneia TZANNOU
  • Publication number: 20220251508
    Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 11, 2022
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
  • Publication number: 20220169986
    Abstract: Embodiments of the disclosure concern multi-respiratory vims specific T cell lines and methods of using the same to treat and prevent viral infections.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 2, 2022
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes
  • Publication number: 20220001005
    Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 6, 2022
    Inventors: Ann Marie Leen, Pailbel Aguayo-Hiraldo, Ifigeneia Tzannou, Juan F. Vera Valdes
  • Publication number: 20210348127
    Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 11, 2021
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann